Physician profile
Ivor Geft
NPI 1043271620
$3,919.22
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $613 · 2021: $671 · 2022: $935 · 2023: $710 · 2024: $85.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,061.89 | 2019-2023 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $780.83 | 2020-2023 | Xifaxan, Trulance, Relistor |
| Novartis Pharmaceuticals Corporation | $196.59 | 2019-2023 | |
| Abbvie INC. | $192.63 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $176.25 | 2019 | |
| Daiichi Sankyo INC. | $161.61 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $159.16 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $156.78 | 2020-2022 | |
| Boston Scientific Corporation | $123.30 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $121.96 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $109.12 | 2021-2023 | |
| Baxter Healthcare | $89.75 | 2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Pfizer INC. | $70.18 | 2019-2023 | |
| Alfasigma USA, INC. | $62.69 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.21 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $49.13 | 2022-2023 | Stelara |
| Regeneron Healthcare Solutions, INC. | $48.89 | 2019-2023 | Dupixent |
| Qol Medical, LLC | $42.51 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $39.88 | 2020-2021 | |
| Ardelyx, INC. | $35.00 | 2022-2023 | Ibsrela |
| Astrazeneca Pharmaceuticals Lp | $33.37 | 2020-2021 | |
| Redhill Biopharma INC. | $24.46 | 2021 | |
| Abbott Laboratories | $21.42 | 2019 | |
| Genzyme Corporation | $19.43 | 2023 | |
| Dexcom, INC. | $17.67 | 2021 | |
| Lilly USA, LLC | $17.45 | 2019 | |
| Gilead Sciences, INC. | $17.12 | 2019 | |
| Esperion Therapeutics, INC. | $16.96 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.86 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivor Geft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.